Epigenetic regulation of immune escape genes in cancer

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2006-05-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-006-0164-4PMID 16680460PMCID PMC11031009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.

  2008cited by this paper
• Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma.

  2006cited by this paper
• A microRNA expression signature of human solid tumors defines cancer gene targets

  2006cited by this paper
• Depletion of Latent HIV-1 Infection In Vivo: A Proof-of-Concept Study

  2006cited by this paper
• Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions

  2006cited by this paper
• Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.

  2006cited by this paper
• The epigenetic progenitor origin of human cancer

  2006cited by this paper
• [Cancer epigenetics].

  2006cited by this paper
• The major histocompatibility complex class II transactivator is differentially regulated by interferon-gamma and transforming growth factor-beta in microglial cells.

  2006cited by this paper
• The major histocompatibility complex class II transactivator is differentially regulated by interferon-γ and transforming growth factor-β in microglial cells

  2006cited by this paper
• Predicting Tumor Outcome following Cancer Vaccination by Monitoring Quantitative and Qualitative CD8+ T Cell Parameters1

  2006cited by this paper
• Innate immune cells contribute to the IFN-gamma-dependent regulation of antigen-specific CD8+ T cell homeostasis.

  2006cited by this paper
• CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer1

  2006cited by this paper
• Cutting Edge: Innate Immune Cells Contribute to the IFN-γ-Dependent Regulation of Antigen-Specific CD8+ T Cell Homeostasis1

  2006cited by this paper
• Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

  2006cited by this paper
• Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A

  2006cited by this paper
• Silencing of microRNAs in vivo with ‘antagomirs’

  2005cited by this paper
• The many roads to cross-presentation

  2005cited by this paper
• In vivo RNA Interference–Mediated Ablation of MDR1 P-Glycoprotein

  2005cited by this paper
• MicroRNA expression profiles classify human cancers

  2005cited by this paper
• Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma.

  2005cited by this paper
• Immune Selection of Hot-Spot β2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy1

  2005influential reference
• DNA methyltransferase inhibitors and the development of epigenetic cancer therapies.

  2005cited by this paper
• Histone modification in the TGFβRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines

  2005cited by this paper
• Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

  2005cited by this paper
• Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

  2005cited by this paper
• Phylogenetic shadowing and computational identification of human microRNA genes.

  2005cited by this paper
• Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.

  2005cited by this paper
• hDOT1L links histone methylation to leukemogenesis.

  2005cited by this paper
• Silence from within: endogenous siRNAs and miRNAs.

  2005cited by this paper
• The dynamics of chromatin remodeling at promoters.

  2005cited by this paper
• Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways.

  2005cited by this paper
• Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

  2005cited by this paper
• Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.

  2005cited by this paper
• Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.

  2005cited by this paper
• Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review

  2005cited by this paper
• Immunotherapy and chemotherapy — a practical partnership

  2005cited by this paper
• The potential of exosomes in immunotherapy of cancer.

  2005cited by this paper
• Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.

  2005cited by this paper
• Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

  2005cited by this paper
• Phase I–II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer

  2005cited by this paper
• Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells.

  2005influential reference
• Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.

  2005cited by this paper
• Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

  2005cited by this paper
• Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.

  2005cited by this paper
• Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

  2005cited by this paper
• MicroRNAs as oncogenes and tumor suppressors.

  2005cited by this paper
• Close encounters of different kinds: Dendritic cells and NK cells take centre stage

  2005cited by this paper
• Akt Phosphorylation of p300 at Ser-1834 Is Essential for Its Histone Acetyltransferase and Transcriptional Activity

  2005cited by this paper
• miR-15 and miR-16 induce apoptosis by targeting BCL2.

  2005cited by this paper
• Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer

  2005cited by this paper
• Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.

  2005cited by this paper
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy

  2005cited by this paper
• Increase in platelet count in older, poor‐risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all‐trans retinoic acid

  2005cited by this paper
• Identification and Characterization of a Novel Human Histone H3 Lysine 36-specific Methyltransferase*

  2005cited by this paper
• Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.

  2005cited by this paper
• Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

  2005cited by this paper
• Promotion of cell differentiation, and suppression of cell growth and cyclooxygenase-2 expression by differentiation-inducing agents in human oral squamous carcinoma SCC25 cells.

  2005cited by this paper
• Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

  2005cited by this paper
• Immunosuppressive networks in the tumour environment and their therapeutic relevance

  2005cited by this paper
• MicroRNA biogenesis and cancer.

  2005cited by this paper
• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

  2005cited by this paper
• Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes.

  2005cited by this paper
• Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.

  2005cited by this paper
• An epigenetic code for DNA damage repair pathways?

  2005cited by this paper
• Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression.

  2005cited by this paper
• The therapeutic potential of RNA interference

  2005cited by this paper
• CpG island methylation of DNA damage response genes in advanced ovarian cancer.

  2005cited by this paper
• Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

  2005cited by this paper
• MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.

  2005cited by this paper
• Cancer epigenetics.

  2005cited by this paper
• The role of the RNAi machinery in heterochromatin formation.

  2005cited by this paper
• Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9

  2005cited by this paper
• DNA Methylation and Demethylation as Targets for Anticancer Therapy

  2005cited by this paper
• Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.

  2005cited by this paper
• The dynamics of histone H1 function in chromatin.

  2005cited by this paper
• Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer

  2005cited by this paper
• Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression

  2005cited by this paper
• Arginine methylation an emerging regulator of protein function.

  2005cited by this paper
• Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.

  2005cited by this paper
• The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

  2005influential reference
• A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

  2005cited by this paper
• Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies

  2005cited by this paper
• Escort service for cross-priming

  2005cited by this paper
• Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ

  2005cited by this paper
• A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop.

  2005cited by this paper
• Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

  2005cited by this paper
• Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes.

  2005cited by this paper
• PLASMA PHARMACOKINETICS AND METABOLISM OF THE HISTONE DEACETYLASE INHIBITOR TRICHOSTATIN A AFTER INTRAPERITONEAL ADMINISTRATION TO MICE

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Current developments of immunotherapy in the clinic.

  2004cited by this paper
• Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells

  2004cited by this paper
• Formalin-fixed tumor cells effectively induce antitumor immunity both in prophylactic and therapeutic conditions.

  2004cited by this paper
• Optimal Use of a Panel of Methylation Markers with GSTP1 Hypermethylation in the Diagnosis of Prostate Adenocarcinoma

  2004cited by this paper
• Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.

  2004cited by this paper
• Apicidin potentiates the imatinib‐induced apoptosis of Bcr–Abl‐positive human leukaemia cells by enhancing the activation of mitochondria‐dependent caspase cascades

  2004cited by this paper
• Human SWI/SNF-Associated PRMT5 Methylates Histone H3 Arginine 8 and Negatively Regulates Expression of ST7 and NM23 Tumor Suppressor Genes

  2004cited by this paper
• Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

  2004cited by this paper
• Epigenetics in human disease and prospects for epigenetic therapy

  2004cited by this paper
• An epigenetically altered tumor cell vaccine

  2004cited by this paper

• Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche

  2025cites this paper
• Beyond the genome: epigenetic regulation of immune responses and T cells in brain tumors

  2025cites this paper
• Systematic analysis of the aberrances and functional implications of epigenetic genes in hepatocellular carcinoma

  2025cites this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cites this paper
• Understanding the role of DNA methylation in colorectal cancer: Mechanisms, detection, and clinical significance.

  2024cites this paper
• Trichostatin A-modified vaccine provides superior protection against ovarian cancer formation and development

  2024cites this paper
• Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit

  2024cites this paper
• Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies

  2023cites this paper
• Células T modificadas con receptores quiméricos de antígeno: ingeniería genética y aplicaciones clínicas en cáncer pediátrico. Revisión de la literatura

  2023cites this paper
• Regulatory mechanisms and clinical applications of tumor-driven exosomal circRNAs in cancers

  2023cites this paper
• Molecular landscape of immune pressure and escape in aplastic anemia

  2022cites this paper
• Epigenetic Drugs and Their Immune Modulating Potential in Cancers

  2022cites this paper
• Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications

  2021cites this paper
• The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy

  2021cites this paper
• Nanomedicine-mediated ubiquitination inhibition boosts antitumor immune response via activation of dendritic cells

  2021cites this paper
• Spotlight on TAP and its vital role in antigen presentation and cross-presentation.

  2021cites this paper
• Systems Biology Resources and Their Applications to Understand the Cancer

  2021cites this paper
• DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application

  2021cites this paper
• A Seven Immune-Related lncRNAs Model to Increase the Predicted Value of Lung Adenocarcinoma

  2020cites this paper
• Marek’s disease vaccines-induced differential expression of known and novel microRNAs in primary lymphoid organ bursae of White Leghorn

  2020cites this paper
• Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance.

  2020cites this paper
• Translational studies of metastatic melanoma in the era of immunotherapy - from humanized mouse models to clinical trials

  2020cites this paper
• Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy

  2019cites this paper
• Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy

  2019cites this paper
• Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment “jigsaw puzzle”

  2019cites this paper
• Epigenetics Analysis and Integrated Analysis of Multiomics Data, Including Epigenetic Data, Using Artificial Intelligence in the Era of Precision Medicine

  2019cites this paper
• Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

  2019cites this paper
• Targeting epigenetic machinery: Emerging novel allosteric inhibitors.

  2019cites this paper
• Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.

  2019cites this paper
• Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?

  2019cites this paper
• Repurposing of Drugs for Immunotherapy

  2018cites this paper
• Epigenetic Changes of the Immune System with Role in Tumor Development.

  2018cites this paper
• The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer

  2018cites this paper
• Epigenetic View on Interferon γ Signalling in Tumour Cells.

  2018cites this paper
• Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines

  2018cites this paper
• Marked for death: targeting epigenetic changes in cancer

  2017cites this paper
• Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?

  2017cites this paper
• Methylated claudin-11 associated with metastasis and poor survival of colorectal cancer

  2017cites this paper
• No patient left behind: The promise of immune priming with epigenetic agents

  2017cites this paper
• Histone Acetylation and the Regulation of Major Histocompatibility Class II Gene Expression.

  2017cites this paper
• Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma.

  2017cites this paper
• Clinical significance of promoter hypermethylation of genes in ovarian cancer

  2017cites this paper
• Immunogenicity and tumour microenvironment in the zebrafish xenograft model

  2017cites this paper
• Leprosy as a model to understand cancer immunosurveillance and T cell anergy

  2016cites this paper
• Essential role of HDAC6 in the regulation of PD‐L1 in melanoma

  2016cites this paper
• Improving cancer immunotherapy with DNA methyltransferase inhibitors

  2016cites this paper
• DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer

  2016cites this paper
• Rewiring the solid tumor epigenome for cancer therapy

  2016cites this paper
• T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

  2015cites this paper
• Epigenetic changes within the promoter regions of antigen processing machinery family genes in Kazakh primary esophageal squamous cell carcinoma.

  2015cites this paper
• Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation

  2015cites this paper
• WHSC 1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck

  2015cites this paper
• Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma

  2015cites this paper
• Nanoparticulate immunotherapy for cancer.

  2015cites this paper
• Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments.

  2015cites this paper
• Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity

  2015cites this paper
• Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes

  2014cites this paper
• 5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.

  2014influential citation
• WHSC1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck

  2014cites this paper
• Epigenetic drugs as immunomodulators for combination therapies in solid tumors.

  2014cites this paper
• Regulation of the Jak/STATs Pathways by Histone Deacetylases

  2014cites this paper
• DNA demethylating agent 5‐azacytidine inhibits myeloid‐derived suppressor cells induced by tumor growth and cyclophosphamide treatment

  2014cites this paper
• Overcoming immune system evasion by personalized immunotherapy.

  2014cites this paper
• Study of the immunological phenotype of metastases obtained from mice receiving different immonotherapy protocols

  2013cites this paper
• Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors

  2013influential citation
• Epigenetic Approaches: Emerging Role of Histone Deacetylase Inhibitors in Cancer Immunotherapy

  2013cites this paper
• An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.

  2013cites this paper
• Alterations of immune response of non-small cell lung cancer with Azacytidine

  2013cites this paper
• Therapeutics , Targets , and Chemical Biology An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

  2013cites this paper
• Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.

  2013cites this paper
• LMP gene promoter hypermethylation is a mechanism for its down regulation in Kazak’s esophageal squamous cell carcinomas

  2013cites this paper
• A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma

  2012cites this paper
• Modulation of antigen‐presenting cells by HDAC inhibitors: implications in autoimmunity and cancer

  2012cites this paper
• Role of Nucleosome Remodeling Factor (NURF) in Tumorigenesis Using a Breast Cancer Mouse Model

  2012cites this paper
• Colorectal carcinoma under microscopy: patohistology or much more?

  2012cites this paper
• Vorklinische Untersuchungen zur Wirkung einer Tumorvakzine in der Therapie Human Papillomvirus-assoziierter Tumorerkrankungen

  2012cites this paper
• Interferon Regulatory Factor-8 Is Important for Histone Deacetylase Inhibitor-Mediated Antitumor Activity

  2012cites this paper
• Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice

  2012cites this paper
• The potential beneficial effects of drugs on the immune response to vaccination.

  2012cites this paper
• Epigenetic code and self-identity.

  2012cites this paper
• Post-Transcriptional and Epigenetic Regulation of Antigen Processing Machinery (APM) Components and HLA-I in Cervical Cancers from Uighur Women

  2012cites this paper
• Transcriptional Modulation Using Histone Deacetylase Inhibitors for Cancer Immunotherapy

  2011cites this paper
• Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses

  2011cites this paper
• Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective

  2011cites this paper
• Interactions of dendritic cells with cancer cells and modulation of surface molecules affect functional properties of CD8+ T cells.

  2011cites this paper
• Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status

  2011cites this paper
• Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.

  2011cites this paper
• Histone Deacetylase Inhibitor LAQ824 Augments Inflammatory Responses in Macrophages through Transcriptional Regulation of IL-10

  2011cites this paper
• Regulation of IL-10 Macrophages through Transcriptional Augments Inflammatory Responses in Histone Deacetylase Inhibitor LAQ824

  2011cites this paper
• Role of Gene Methylation in Antitumor Immune Response: Implication for Tumor Progression

  2011cites this paper
• Immunosuppression associée à l’enzyme interleukine-4 induced gene 1 (IL4I1) : régulation de l’expression dans les cellules humaines et rôle dans l’échappement tumoral à la réponse immune dans un modèle murin

  2011cites this paper
• Circumventing immune tolerance through epigenetic modification.

  2010cites this paper
• Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome

  2010cites this paper
• “Smart” nanomaterials for cancer therapy

  2010cites this paper
• Immunotherapy of MHC class I-deficient tumors.

  2010cites this paper
• Immunoinformatics and systems biology methods for personalized medicine.

  2010cites this paper
• MHC class II regulation by epigenetic agents and microRNAs

  2010cites this paper
• Combining T-cell Vaccination and Application of Agonistic Anti-GITR mAb (DTA-1) Induces Complete Eradication of HPV Oncogene Expressing Tumors in Mice

  2010cites this paper
• Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

  2009cites this paper
• Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis

  2009cites this paper